Clinical Drug Investigation

, Volume 19, Issue 2, pp 111–121

Zanamivir, a New Targeted Therapy in the Treatment of Influenza

A Patient Perspective Assessed by Questionnaire
Clinical Use

Abstract

Objective: A patient survey was conducted by questionnaire to evaluate patient acceptance and perceptions of efficacy with zanamivir (Glaxo Wellcome), the first in a new class of neuraminidase inhibitors that are active against both influenza A and influenza B. The survey was also designed to provide rapid feedback to physicians prescribing zanamivir within the winter period when influenza was likely to be prevalent.

Setting: Patients with clinically diagnosed influenza were enrolled by participating general practitioners (GPs) during the 1999 influenza season in Australia. Courses of medication with a questionnaire were prescribed by participating GPs.

Patients: A total of 1408 patients returned completed questionnaires, 60% were employed or were students and 238 had had a current influenza immunisation, mostly patients >65 years. Myalgia, headache and feverishness were reported by at least 80% of patients.

Results: Symptom relief was reported by more than 50% of patients within 24 hours and by 77% of patients within 48 hours; satisfaction with treatment was high and 65% of patients returned to normal activities within 72 hours. Older patients reported a slightly less rapid response to zanamavir in terms of symptom relief, but nevertheless were able to return quickly to normal activities. A total of 378/477 (79%) patients who were very satisfied with their treatment experienced symptom relief in 24 hours. Of the 400 at-risk patients aged >65 years or with co-morbidities, 78% were satisfied with their treatment, with 235/400 (59%) experiencing symptom relief within 24 hours. Patients found the Diskhaler™ device easy to use irrespective of age and reported rapid symptom relief, which may reflect the targeted delivery of high concentrations of zanamivir to the site of viral replication in the respiratory tract.

Conclusion: Overall, the survey indicated that zanamivir was associated with an early return to normal activities and confirmed that the benefits observed with the drug in controlled clinical trials were extrapolated to community practice.

References

  1. 1.
    Morbidity and Mortality Weekly Report 1999; 48 (29): 623Google Scholar
  2. 2.
    Osterhaus A. H5N1: the lessons learned. In: Zambon MC, editor. Advances in influenza. International Medical Forum 104. Oxford: Blackwell Science Ltd, 1999Google Scholar
  3. 3.
    Aoki FY. Amantidine and rimantidine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 457–76Google Scholar
  4. 4.
    Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275(4): 295–9PubMedCrossRefGoogle Scholar
  5. 5.
    Aoki FY, Hayden FG. The pharmacokinetics of Zanamivir: a new inhaled antiviral for influenza. Clin Pharmacokinet 1999; 36Suppl. 1: 1–58Google Scholar
  6. 6.
    Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874–80PubMedCrossRefGoogle Scholar
  7. 7.
    Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomised controlled trial. JAMA 1999; 282(1): 31–5PubMedCrossRefGoogle Scholar
  8. 8.
    The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352(9144): 1877–81CrossRefGoogle Scholar
  9. 9.
    Monto AS, Webster A, Keene O. Randomised, placebo controlled studies of inhaled zanamivir in the treatment of influenza A and B -pooled efficacy analysis. J Antimicrob Chemother 1999; 44 Topic B: 23–9PubMedCrossRefGoogle Scholar
  10. 10.
    von Itzstein I, Wu W-Y, Kok G, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23CrossRefGoogle Scholar
  11. 11.
    Zanamivir Prescribing Information Glaxo Wellcome, Boronia Australia 1999Google Scholar
  12. 12.
    National Centre for Disease Control, Commonwealth Department of Health and Aged Care and Communicable Diseases Network of Australia and New Zealand. Communicable Diseases Intelligence, Australia (internet site:http://www.health.gov.au/pubhlth/cdi)
  13. 13.
    Glaxo Wellcome. Data on fileGoogle Scholar
  14. 14.
    Nicholson KG. Epidemiology. In: Nicholson KG editor. Managing influenza in primary care. Oxford: Blackwell Science Ltd, 1999: 26Google Scholar
  15. 15.
    Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science Ltd, 1998: 358–72Google Scholar
  16. 16.
    Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Black-well Science Ltd, 1998: 219–64Google Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Monash Medical CentreClaytonAustralia
  2. 2.The Investigator ClinicPort LincolnAustralia

Personalised recommendations